HC Wainwright Analysts Boost Earnings Estimates for Bausch + Lomb Co. (NYSE:BLCO)

Bausch + Lomb Co. (NYSE:BLCO - Free Report) - Research analysts at HC Wainwright boosted their Q4 2024 earnings per share (EPS) estimates for Bausch + Lomb in a research report issued to clients and investors on Thursday, May 2nd. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.36 per share for the quarter, up from their prior forecast of $0.25. HC Wainwright currently has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Bausch + Lomb's current full-year earnings is $0.66 per share. HC Wainwright also issued estimates for Bausch + Lomb's FY2025 earnings at $1.03 EPS.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last announced its earnings results on Wednesday, May 1st. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). Bausch + Lomb had a negative net margin of 7.81% and a positive return on equity of 3.60%. The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the company earned $0.10 EPS. Bausch + Lomb's revenue was up 18.0% compared to the same quarter last year.

BLCO has been the subject of several other research reports. Wells Fargo & Company increased their price target on Bausch + Lomb from $21.00 to $23.00 and gave the company an "overweight" rating in a report on Thursday, February 22nd. Evercore ISI increased their price target on Bausch + Lomb from $16.50 to $17.00 and gave the company an "in-line" rating in a report on Thursday, April 4th. Royal Bank of Canada cut their price target on Bausch + Lomb from $20.00 to $18.00 and set an "outperform" rating for the company in a report on Monday, April 22nd. Barclays increased their price target on Bausch + Lomb from $17.00 to $18.00 and gave the company an "equal weight" rating in a report on Monday, February 26th. Finally, Evercore cut their target price on Bausch + Lomb from $17.00 to $15.00 and set an "in-line" rating for the company in a research note on Thursday. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $19.45.

Bausch + Lomb Price Performance

Shares of NYSE:BLCO traded up $0.85 during midday trading on Monday, hitting $14.45. The company had a trading volume of 1,496,352 shares, compared to its average volume of 502,297. Bausch + Lomb has a twelve month low of $13.16 and a twelve month high of $21.95. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.03. The stock has a market cap of $5.08 billion, a price-to-earnings ratio of -15.04, a price-to-earnings-growth ratio of 1.35 and a beta of 0.47. The business's 50-day simple moving average is $15.76 and its 200-day simple moving average is $15.58.

Institutional Trading of Bausch + Lomb

Several hedge funds have recently made changes to their positions in BLCO. Renaissance Capital LLC raised its position in Bausch + Lomb by 3.0% in the 1st quarter. Renaissance Capital LLC now owns 23,076 shares of the company's stock valued at $399,000 after purchasing an additional 669 shares in the last quarter. Gabelli Funds LLC lifted its stake in Bausch + Lomb by 2.3% in the third quarter. Gabelli Funds LLC now owns 263,744 shares of the company's stock worth $4,470,000 after acquiring an additional 6,017 shares during the last quarter. Black Swift Group LLC acquired a new position in Bausch + Lomb during the 3rd quarter worth approximately $170,000. Brandes Investment Partners LP increased its position in shares of Bausch + Lomb by 11.0% in the 4th quarter. Brandes Investment Partners LP now owns 114,200 shares of the company's stock valued at $1,948,000 after purchasing an additional 11,321 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in Bausch + Lomb in the third quarter valued at $255,000. Institutional investors and hedge funds own 11.07% of the company's stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.